James H. Wikel

Jim served in a variety of positions from the time he joined Eli Lilly in 1971 to 2001 as a scientist and research manager including Head, Structural and Computational Sciences, Discovery Chemistry Research & Technologies as well as Senior Research Scientist. He has 34 peer-reviewed scientific publications and 47 issued U.S. Patents. The subject matter included in these patents and publications describe 3 molecules that underwent clinical evaluation as drug candidates—enviroxime, enviradene, and frentizole—and one successfully marketed agricultural product, BEAM. As a computational chemistry scientist, he has published in a broad range of topics with expertise in QSAR studies and algorithm development. He established the QSAR group at The Lilly Research Labs and initiated the development of proprietary predictive methods. Jim was Chief Technology Officer of Coalesix Inc., a start up company in Cambridge, MA, from 2005 until it became a division of Icosystem Inc. in December 2006. His experiences enable him to understand and translate among the disciplines of chemistry, biology, and statistics to enable medicinal chemists to optimize molecules for development using both predictive models and empirical approaches. He has a Bachelor of Science degree in Chemistry and a Master of Science degree in Organic Chemistry, both from Marshall University.